Skip to content

   Pharma Publications

Neuropsychopharmacology
  • UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice
    Published on 2023-05-29
    3 years ago
  • How should we design future mechanistic and/or efficacy clinical trials?
    Published on 2023-05-26
    3 years ago
  • Region- and time- specific effects of ketamine on cerebral blood flow: a randomized controlled trial
    Published on 2023-05-25
    3 years ago
  • Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants
    Published on 2023-05-25
    3 years ago
  • Dopamine D2 receptors in nucleus accumbens cholinergic interneurons increase impulsive choice
    Published on 2023-05-23
    3 years ago
  • Involvement of cortical input to the rostromedial tegmental nucleus in aversion to foot shock
    Published on 2023-05-23
    3 years ago
  • Accelerated TMS – moving quickly into the future of depression treatment
    Published on 2023-05-22
    3 years ago
« Previous 1 … 135 136 137 138 139 … 143 Next »
Journal of Psychopharmacology
  • Serotonin type 5A receptor antagonists inhibit D-lysergic acid diethylamide discriminatory cue in rats
    Published on 2019-08-27
    7 years ago
  • Memory impairment following intentional self-poisoning with benzodiazepines: Should we pay more attention to attention?
    Published on 2019-08-21
    7 years ago
  • Transient receptor potential vanilloid 1 mediates cocaine reinstatement via the D1 dopamine receptor in the nucleus accumbens
    Published on 2019-08-21
    7 years ago
  • Characteristics of deaths associated with kratom use
    Published on 2019-08-20
    7 years ago
  • Evaluation of agomelatine for the treatment of sleep problems in adults with autism spectrum disorder and co-morbid intellectual disability
    Published on 2019-08-19
    7 years ago
  • Developing a phone-based measure of impairment after acute oral ∆9-tetrahydrocannabinol
    Published on 2019-08-13
    7 years ago
  • Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review
    Published on 2019-07-26
    7 years ago
« Previous 1 … 135 136 137 138 139 … 154 Next »
European Neuropsychopharmacology
  • P.849A five-year follow up study of a naturalistic cohort treated with long-acting injectable antipsychotics
    Published on 2020-11-25
    6 years ago
  • P.820Pharmacological inhibition of soluble epoxide hydrolase protects cognitive impairment in a Niemann-Pick mice model
    Published on 2020-11-25
    6 years ago
  • P.850Real-world effectiveness of aripiprazole long-acting injectable
    Published on 2020-11-25
    6 years ago
  • P.824Positive and negative symptoms, cognitive deficits and antipsychotic treatment in schizophrenic patients
    Published on 2020-11-25
    6 years ago
  • P.851Differences in healthcare resource utilization across oral atypical antipsychotic treatments in patients with schizophrenia
    Published on 2020-11-25
    6 years ago
  • P.829Clinical characteristics of schizophrenia offspring, children diagnosed with attention deficit hiperactivity disorder and healthy controls
    Published on 2020-11-25
    6 years ago
  • P.855Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: pooled analysis of double-blind, placebo-controlled 6-week studies
    Published on 2020-11-25
    6 years ago
« Previous 1 … 135 136 137 138 139 … 170 Next »

   Pharma Pub